| Literature DB >> 21804771 |
Ahmed A Al-Amiery1, Yasmien K Al-Majedy, Haziem Abdulreazak, Hussain Abood.
Abstract
Problem Statement. In Iraq like most third world countries, attempts discovered new antibiotic drugs derived from thiosemicarbazide and its metal complexes and developed the branch of applied in organic chemistry. Approach. New (Z)-2-(pyrrolidin-2-ylidene)hydrazinecarbothioamide (L) was synthesized in a good yield by the reaction of pyrrolidone with thiosemicarbazide. Co(II), Ni(II), and Cu(II) complexes of (L) were prepared and characterized by FT-IR, UV/visible spectra, (1)HNMR, and CHN analyses. Moreover, charge, bond length, bond angle, twist angle, heat of formation, and steric energy were calculated by using of the ChemOffice program, and the DFT calculations for the complexes were done. The free ligand and its metal complexes were tested in vitro against several microorganisms (Staphylococcus aurous, E. coli, Proteus vulgaris, Pseudomonas, and Klebsiella pneumoniae) to assess their antimicrobial properties. Results. The study shows that these complexes have octahedral geometry; in addition, it has high activity against tested bacteria. Conclusion/Recommendations. Based on the reported results, it may be concluded that ligand acts as bidentate, neutral ligand, coordinating through one of the nitrogen and sulfur atoms.Entities:
Year: 2011 PMID: 21804771 PMCID: PMC3143429 DOI: 10.1155/2011/483101
Source DB: PubMed Journal: Bioinorg Chem Appl Impact factor: 7.778
Scheme 1Conductivity, colors, and elemental analysis data of the complexes.
| NO. | Complex | Yield % | M.P. °C | Analysis: Found (cal.) % | M : L | Color | Ωm ohm−1
| |||
|---|---|---|---|---|---|---|---|---|---|---|
| Metal | C | H | N | |||||||
| C1 | Co(C5H10N4S)2Cl2 | 75 | Over 300 | 13.21 (12.7) | 24.91 (26.4) | 4.52 (4.22) | 24.11 (24.87) | 1 : 2 | Dark brown | 30 |
| C2 | Ni(C5H10N4S)2Cl2 | 60 | Over 300 | 13.16 (12.65) | 23.93 (25.12) | 4.52 (4.12) | 25.12 (24.16) | 1 : 2 | Light green | 65 |
| C3 | Cu(C5H10N4S)2Cl2 | 77 | 260 | 14.09 (13.39) | 23.64 (25.94) | 4.47 (4.30) | 23.85 (24.43) | 1 : 2 | Green | 30 |
Figure 2Antibacterial activity of the ligand and its metal complexes.
Infrared absorption frequencies (cm−1) of Co(II), Ni(II), and Cu(II) complexes.
| Compounds |
|
|
|
|
|
| v(M–S) | v(M–Cl) |
|---|---|---|---|---|---|---|---|---|
| Ligand | 3395 s, 3275 s | 1600 s | 1330 s, 1200 m | 1035 m | 855 s, 770 s | — | — | — |
| C1 | 3330 m, 3265 m | 1570 s | 1380 s, 1240 m | 1075 m | 850 s, 780 m | 525 m | 440 m | 350 w |
| C2 | 3320 m, 3260 m | 1565 s | 1380 s, 1235 m | 1070 m | 835 s, 780 m | 535 m | 420 m | 355 w |
| C3 | 3385 m, 3275 m | 1575 s | 1365 s, 1240 m | 1060 m | 840 s, 795 m | 520 m | 430 m | 360 m |
Figure 1Structures of the complexes.
Bond lengths of the ligand.
| Bond | Actual | Optimal | Bond | Actual | Optimal | Bond | Actual | Optimal |
|---|---|---|---|---|---|---|---|---|
| N(2)–H(11) | 1.0117 | 1.0120 | C(8)–H(15) | 1.1188 | 1.1130 | N(5)–H(13) | 0.9906 | 1.0120 |
| H(20)–C(10) | 1.1242 | 1.1130 | C(9)–C(8) | 1.5256 | 1.5230 | H(12)–N(5) | 0.9929 | 1.0120 |
| C(10)–H(19) | 1.1246 | 1.1130 | C(7)–N(1) | 1.3204 | 1.2600 | C(3)–N(5) | 1.3652 | 1.3690 |
| H(18)–C(9) | 1.1167 | 1.1130 | C(7)–C(8) | 1.5251 | 1.4970 | C(3)–S(4) | 1.6285 | 1.5760 |
| C(9)–H(17) | 1.1169 | 1.1130 | H(14)–N(6) | 0.9976 | 1.0500 | N(2)–C(3) | 1.4145 | 1.3690 |
| C(10)–C(9) | 1.5399 | 1.5230 | C(10)–N(6) | 1.4571 | 1.4700 | N(1)–N(2) | 1.3414 | |
| C(8)–H(16) | 1.1188 | 1.1130 | C(7)–N(6) | 1.4224 | 1.4620 |
Bond angles of the ligand.
| Angle | Actual | Optimal | Angle | Actual | Optimal |
|---|---|---|---|---|---|
| H(20)–C(10)–H(19) | 108.0742 | 109.4000 | C(7)–C(8)–H(15) | 110.1767 | 109.4100 |
| H(20)–C(10)–C(9) | 110.8390 | 109.4100 | C(7)–C(8)–C(9) | 105.3224 | 109.5000 |
| H(20)–C(10)–N(6) | 107.3801 | N(1)–C(7)–C(8) | 128.1179 | 115.1000 | |
| H(19)–C(10)–C(9) | 110.4255 | 109.4100 | N(1)–C(7)–N(6) | 121.7403 | 126.0000 |
| H(19)–C(10)–N(6) | 111.8302 | C(8)–C(7)–N(6) | 110.0955 | 125.3000 | |
| C(9)–C(10)–N(6) | 108.2648 | C(10)–N(6)–H(14) | 115.3567 | ||
| H(18)–C(9)–H(17) | 108.0210 | 109.4000 | C(7)–N(6)–H(14) | 116.0931 | 118.0000 |
| H(18)–C(9)–C(10) | 110.5216 | 109.4100 | C(7)–N(6)–C(10) | 109.1525 | |
| H(18)–C(9)–C(8) | 111.1762 | 109.4100 | H(12)–N(5)–H(13) | 119.3842 | 118.8000 |
| C(10)–C(9)–H(17) | 110.4261 | 109.4100 | C(3)–N(5)–H(13) | 123.4115 | |
| H(17)–C(9)–C(8) | 110.9742 | 109.4100 | H(12)–N(5)–C(3) | 117.1111 | |
| C(10)–C(9)–C(8) | 105.7415 | 109.5000 | N(5)–C(3)–S(4) | 122.0027 | 124.3000 |
| H(15)–C(8)–H(16) | 108.4617 | 109.4000 | N(2)–C(3)–N(5) | 120.9560 | 120.0000 |
| C(9)–C(8)–H(16) | 111.3872 | 109.4100 | N(2)–C(3)–S(4) | 116.9829 | 124.3000 |
| C(7)–C(8)–H(16) | 110.1951 | 109.4100 | C(3)–N(2)–H(11) | 112.0942 | 117.4000 |
| C(9)–C(8)–H(15) | 111.2857 | 109.4100 | N(1)–N(2)–H(11) | 120.3309 | |
| C(10)–C(9)–H(17) | 110.4261 | 109.4100 | N(1)–N(2)–C(3) | 122.2156 |
Atomic charge of the ligand.
| Charges | Atoms | Charges | Atoms | Charges | Atoms | Charges | Atoms |
|---|---|---|---|---|---|---|---|
| N −0.431 | [N(1)] | N 0.081 | [N(6)] | H 0.068 | [H(11)] | H 0.040 | [H(16)] |
| N 0.263 | [N(2)] | C 0.222 | [C(7)] | H 0.101 | [H(12)] | H 0.031 | [H(17)] |
| C 0.233 | [C(3)] | C | [C(8)] | H 0.104 | [H(13)] | H 0.028 | [H(18)] |
| S −0.696 | [S(4)] | C | [C(9)] | H 0.091 | [H(14)] | H 0.011 | [H(19)] |
| N −0.049 | [N(5)] | C 0.036 | [C(10)] | H 0.038 | [H(15)] | H 0.018 | [H(20)] |
Figure 3The 3d-geometrical structure for the ligand.